EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center



Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center



Aids and Behavior 20(5): 1068-1075



Continuous HIV treatment is necessary to ensure successful combined antiretroviral therapy (cART). The aim of this study was to evaluate the incidence of patient-initiated non-structured treatment interruptions in HIV-infected persons who inject drugs and who received a multidisciplinary comprehensive program, including medical HIV care, drug-dependence treatment and psychosocial support, at a drug outpatient addiction center. Non-structured treatment interruptions were defined as ≥30 consecutive days off cART without medical indication. During a median follow-up of 53.8 months, 37/132 (28 %) patients experienced the first non-structured treatment interruptions. The cumulative probability of cART interruption at 5 years was 31.2 % (95 % CI 22.4-40.0). Current drug use injection ≥1/day (HR 14.77; 95 % CI 5.90-36.96) and cART naive patients (HR 0.35, 95 % CI 0.14-0.93) were predictive factors for non-structured treatment interruptions. HIV care provided at a drug addiction center is a useful strategy to sustain continuous cART, however, drug abstinence is essential for the long-term maintenance of cART.

(PDF emailed within 0-6 h: $19.90)

Accession: 058240786

Download citation: RISBibTeXText

PMID: 26427376

DOI: 10.1007/s10461-015-1211-y



Related references

Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy. Current HIV Research 10(4): 356-363, 2013

Effectiveness of Antiretroviral Therapy in HIV-1-Infected Active Drug Users Attended in a Drug Abuse Outpatient Treatment Facility Providing a Multidisciplinary Care Strategy. Current HIV Research 10(4): 356-363, 2012

Outcomes According to Discharge Location for Persons Who Inject Drugs Receiving Outpatient Parenteral Antimicrobial Therapy. Open Forum Infectious Diseases 5(5): Ofy056-Ofy056, 2018

Non-antiretroviral drugs uses among HIV-infected persons receiving antiretroviral therapy in Senegal: Costs and factors associated with prescription. Revue D'epidemiologie et de Sante Publique 65(4): 295-300, 2017

C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Nave HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy. Journal of Hepatology 64(2): S403-S404, 2016

Compulsory drug detention exposure is associated with not receiving antiretroviral treatment among people who inject drugs in Bangkok, Thailand: a cross-sectional study. Substance Abuse Treatment, Prevention, and Policy 10(): 16-16, 2015

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clinical Infectious Diseases 40(5): 728-734, 2005

Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine 16(9): 625-633, September, 2001

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences of the United States of America 98(23): 13288-13293, 2001

Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA 285(18): 2355-2362, 2001

Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. Aids 14(15): 2313-2322, 2000

All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection 41(2): 545-551, 2013

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. Aids Research and Human Retroviruses 20(12): 1283-1288, 2005

Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clinical Infectious Diseases 44(9): 1235-1244, 2007

Related factors on secondary drug resistance in HIV infected persons receiving antiretroviral therapy in Shandong province: a case-control study. Zhonghua Liu Xing Bing Xue Za Zhi 39(7): 943-947, 2018